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OBJECTIVES We sought to evaluate approaches used to control rate, the effectiveness of rate control, and
switches from one drug class to another in the Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM) study.
BACKGROUND The AFFIRM study showed that atrial fibrillation (AF) can be treated effectively with rate
control and anticoagulation, but drug efficacy to control rate remains uncertain.
METHODS Patients (n  2,027) randomized to rate control in the AFFIRM study were given
rate-controlling drugs by their treating physicians. Standardized rate-control efficacy criteria
developed a priori included resting heart rate and 6-min walk tests and/or ambulatory
electrocardiographic results.
RESULTS Average follow-up was 3.5  1.3 years. Initial treatment included a beta-adrenergic blocker
(beta-blocker) alone in 24%, a calcium channel blocker alone in 17%, digoxin alone in 16%,
a beta-blocker and digoxin in 14%, or a calcium channel blocker and digoxin in 14% of
patients. Overall rate control was achieved in 70% of patients given beta-blockers as the first
drug (with or without digoxin), 54% with calcium channel blockers (with or without digoxin),
and 58% with digoxin alone. Adequate overall rate control was achieved in 58% of patients
with the first drug or combination. Multivariate analysis revealed an association between first
drug class and several clinical variables. There were more changes to beta-blockers than to the
other two-drug classes (p  0.0001).
CONCLUSIONS Rate control in AF is possible in the majority of patients with AF. Beta-blockers were the
most effective drugs. To achieve the goal of adequate rate control in all patients, frequent
medication changes and drug combinations were needed. (J Am Coll Cardiol 2004;43:
1201–8) © 2004 by the American College of Cardiology Foundationhe general approaches used to manage atrial fibrillation blockers, and digoxin have been compared in small studies
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TAF) include: 1) ventricular rate control, and 2) rhythm
ontrol (attempts to maintain sinus rhythm [SR]), both in
See page 1209
ombination with anticoagulation. Despite the large num-
er of patients treated with rate-controlling therapies for
F, the best pharmacologic approach remains unknown.
eta-adrenergic blockers (beta-blockers), calcium channel
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Manuscript received August 12, 2003; revised manuscript received October 29,r003, accepted November 20, 2003.1–29), but no large trial has determined the optimal
harmacologic method to control the ventricular response
o AF in ambulatory patients.
The Atrial Fibrillation Follow-up Investigation of
hythm Management (AFFIRM) study was a large, mul-
icenter, randomized trial sponsored by the National Heart,
ung, and Blood Institute. This trial compared rate-control
herapy with rhythm-control therapy to treat AF in a
opulation at high risk of stroke or death (30–34). The
rimary goal was to determine which approach was associ-
ted with a better survival outcome. The AFFIRM study
howed that rate control was an acceptable, if not the
referable, option (33). A substudy of this trial offered the
pportunity to evaluate and compare several drug classes for
he long-term ventricular rate control of AF.
ETHODS
his investigation assessed the effectiveness of ventricularate-control approaches in AF in a large, general population
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Rate Control in AFFIRM April 7, 2004:1201–8f predominantly elderly patients. Data on all AFFIRM
tudy patients assigned to the rate-control arm were re-
iewed to determine the effectiveness of rate control by the
rug classes chosen by the treating physician.
The overall AFFIRM study was approved by the AF-
IRM Steering Committee, the Institutional Review Board
f the University of Washington (Clinical Trial Center),
nd by each participating site’s local Institutional Review
oard. All patients gave informed, written consent to
articipate in the AFFIRM study.
efinition of rate control. Prespecified criteria for ade-
uate heart rate (HR) control in AF are outlined in Table 1.
ate control was assessed only if the patient was in AF at
he time of evaluation. If a patient in the rate-control arm
as in SR at a specified visit, rate control was not assessed
nd not recorded at that visit. Adequate rate control
equired the initial resting HR to be 80 beats/min. If that
oal was achieved, a standard 6-min walk test (35) or 24-h
mbulatory electrocardiographic recording (Holter monitor)
as required to confirm adequate rate control. The ap-
roach used was left to the discretion of the treating
hysician. If both Holter monitoring and a 6-min walk test
ere performed, rate-control criteria had to be met for both
ests. Overall rate control required evidence for resting and
xercise rate control, as defined. Tests were repeated until
ate control was achieved or when the patient had a change
n status or change in drug dosage. Further drug titration
as based on the results of these studies. The drug dose was
djusted and optimized by the treating physician in an
ttempt to achieve the preselected rate-control guidelines. If
dequate rate control could not be achieved at a low dosage
f medication, the dose was titrated upward, or a different
edication was used and titrated in an attempt to achieve an
cceptable rate response. If adequate rate control could still
ot be achieved despite a maximally tolerated drug dose, the
reating physician could add another drug. A medication
Abbreviations and Acronyms
AF  atrial fibrillation
AFFIRM  Atrial Fibrillation Follow-up Investigation
of Rhythm Management study
AV  atrioventricular
HF  heart failure
HR  heart rate
MI  myocardial infarction
SR  sinus rhythm
able 1. AFFIRM Definition of Adequate Ventricular Rate
ontrol
. Average heart rate at rest 80 beats/min, and
. Either (A) or (B)
A. Heart rate maximum during a 6-min walk 110 beats/min, or
B. Average heart rate during 24-h ambulatory Holter monitoring
(ECG) 100 beats/min (at least 18 h of interpretable monitoring)
and no heart rate 110% maximum predicted age-adjusted
exercise heart rate Tas stopped if the patient developed adverse effects, such as
orsening congestive heart failure (HF) or hypotension. If a
harmacologic approach was not effective, the treating
hysician could proceed with atrioventricular (AV) junc-
ional ablation, as defined in the protocol (31).
Patients were evaluated at two months using the same
ethods and criteria. The resting HR was determined at
ach routine clinic visit (every four months). A 6-min walk
est or Holter monitoring was to be performed at a mini-
um of once a year, even if no changes had been made in
he drug regimen and no changes were noted in the patient’s
linical status.
hoice of drugs. Patients in the rate-control arm of the
FFIRM study were treated with an AV nodal blocking
rug chosen by their treating physician. Drug choice was
ot randomized and was not expected to be distributed
qually across all patient types or conditions. Treatment
ncluded beta-blockers, calcium channel blockers, or
igoxin, alone or in combination.
ata collection. The primary end point of this study was
dequate “overall” pharmacologic rate control at rest and
ith exercise while taking the initial drug class chosen, after
ose optimization by the treating physician. The adequacy
f rate control was determined sequentially over the entire
eriod of patient follow-up, but the specific end points of
his substudy were: 1) achievement of adequate rate control,
s defined earlier, with the first drug class chosen for each
atient; and 2) the rate of switching from the first drug class
hosen to another drug class.
Only drug classes (not individual drugs) administered
uring the last follow-up period were reported on the data
orms submitted to the Clinical Trial Center. For example,
nly the category of beta-blockers would have been re-
orted, not propranolol, metoprolol, and the like. Drug
oses and start/stop dates were not reported. The rate-
ontrol drug classes were digoxin, beta-blockers, and cal-
ium channel blockers.
Patients were classified by the drug group initially admin-
stered after randomization. Rate control for the initial drug
lass chosen for a patient was defined as the last determi-
ation of rate control while taking that drug before discon-
inuing the drug or adding a new drug. Patients who crossed
ver to rhythm control (248 of 2,027 patients) (33) were
ensored from further analysis at the time of crossover.
tatistics. Baseline comparisons among all four major drug
reatment groups (digoxin alone, beta-blockers with or
ithout digoxin, calcium channel blockers with or without
igoxin, and beta-blockers plus calcium channel blockers
ith or without digoxin) were performed using two-way
hi-square tests for homogeneity for dichotomous variables
r analysis of variance for continuous variables. Drug dis-
ontinuation was assessed using Kaplan-Meier time-to-
vent analysis and log-rank statistics.
Multivariate analyses evaluated the association between
aseline clinical factors and the initial choice of drugs.
hese analyses were performed using linear model tech-
n
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April 7, 2004:1201–8 Rate Control in AFFIRMiques generalized to categorical dependent variables (PROC
ATMOD in SAS, Cary, North Carolina). For these analy-
es, only main effects were included, and a stepwise backward
election method was used. The criteria for remaining in the
odel was p  0.01, as well as the factors associated with the
uccess or failure of the first drug class chosen. The factors
ested included age 65 years, gender, ethnicity, primary
ardiac diagnosis, duration of qualifying AF, history of pulmo-
ary disease, coronary artery disease, congestive HF, hyperten-
ion, diabetes, angina pectoris, myocardial infarction (MI),
revious coronary artery bypass graft surgery or revasculariza-
ion procedure, hepatic or renal disease, qualifying episode
eing the first episode of AF, frequency of episodes of AF,
revious drug failure, left ventricular ejection fraction, left atrial
ize, and baseline HR.
Differences in mortality and long-term symptoms among
rug classes could not be compared because patients were
witched to different drug classes frequently throughout the
tudy. Comparisons of rate control across different groups
ould not be performed for the same reasons; thus, this
rticle is primarily a descriptive report. Furthermore, this
ubstudy did not have sufficient power to detect differences
n mortality among the different drug treatment groups.
ESULTS
his evaluation included the 2,027 patients randomized to
he rate-control arm of the AFFIRM study (Table 2).
verage follow-up was 3.5  1.3 years.
atient demographics and clinical characteristics. Before
ntering the AFFIRM study, 53% of patients had received
igoxin, 40% had received a calcium channel blocker, and
2% a beta-blocker.
Clinical characteristics are listed in Table 3, as catego-
ized by the drug class chosen initially. Significant differ-
nces existed among drug classes with regard to gender,
oronary artery disease, angina pectoris, MI, coronary artery
ypass graft surgery, interventional coronary procedure,
ypertension, cardiomyopathy, pulmonary disease, baseline
R, SR at randomization, previous drug use, and ejection
raction.
Initially, 485 patients (24%) were treated with a beta-
locker alone, 344 (17%) with a calcium channel blocker
lone, and 315 (16%) with digoxin alone. A drug combina-
ion was used frequently—a beta-blocking drug and digoxin
n 292 (14%) and a calcium channel blocker plus digoxin in
87 (14%). Other drugs, other combinations, and no ther-
py accounted for 154 (8%), and missing data accounted for
50 (7%), yielding a total of 304 patients (15%).
The multivariate analysis revealed the following items to be
ssociated with the first drug class used for rate control: gender
p  0.0001), history of coronary artery disease (p  0.0001),
ulmonary disease (p 0.0001), congestive HF (p 0.0001),
ypertension (p  0.0001), qualifying episode being the first
pisode of AF (p  0.005), and baseline HR (p  0.006).
atients were likely to be prescribed the drug being admin- 7stered before randomization. Beta-blockers were more
ikely to be used in patients having coronary disease, angina,
revious MI, and previous coronary interventions. Calcium
hannel blockers were more likely to be used in patients
ith pulmonary disease and in females. Digoxin was used
ore often in patients with cardiomyopathy and in non-
hites (Table 3).
nitial rate control at rest. Rate control at rest was
chieved with a beta-blocker (with or without digoxin) in
able 2. Patient Demographics
AFFIRM Study
Rate-Control Arm
(n  2,027)
ge (yrs) 69.8  8.9
emale gender 823 (40.6)
rimary diagnosis
None apparent 265 (13.1)
CAD 497 (24.5)
Cardiomyopathy 99 (4.9)
Hypertension 1,045 (51.6)
Valvular heart disease 98 (4.8)
Other 23 (1.1)
istory
CAD 757 (37.4)
MI 332 (16.4)
Cardiomyopathy 174 (8.6)
Hypertension 1,434 (70.7)
CHF 475 (23.4)
Angina 515 (25.4)
uration of qualifying AF
6 h 158 (7.8)
6–12 h 217 (10.7)
12–48 h 246 (12.1)
2–30 days 528 (26.1)
30 days to 6 months 755 (37.3)
6 months 123 (6.1)
irst episode 700 (35.8)
rug failures*
Any 364 (18.0)
1 248 (68.1)
2 85 (23.4)
3 31 (8.5)
requency of episodes
Frequent/very frequent† 354 (27.2)
A size‡
Normal 549 (33.3)
Mild enlargement 451 (27.3)
Moderate to severe enlargement 557 (33.8)
VEF§
Normal 1,131 (68.6)
Mild dysfunction 192 (11.6)
Moderate dysfunction 107 (6.5)
Severe dysfunction 81 (4.9)
ean maximum ventricular rate (beats/min) 108.4  32.5
Before randomization. †Meaning more than one symptomatic episode per month
patients presenting with first episodes and patients with asymptomatic AF were
xcluded). These data points were recorded only after July 1, 1997 (n  2,611).
N  3,311 echocardiograms; left atrial size was unknown in 184. §N  3,311
chocardiograms; left ventricular function was unknown in 279. Data are
resented as the mean value  SD or number (%) of patients.
AF  atrial fibrillation; CAD  coronary artery disease; CHF  congestive
eart failure; LA  left atrial; LVEF  left ventricular ejection fraction; MI 
yocardial infarction.5% of patients, with digoxin alone in 68%, and with a
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Rate Control in AFFIRM April 7, 2004:1201–8alcium channel blocker (with or without digoxin) in 66%
Table 4). Similarly, rate control at rest was achieved with a
eta-blocker alone in 68% and with a calcium channel
locker alone in 60%.
nitial rate control during exertion. Beta-blockers (with
r without digoxin) provided rate control during exertion in
5%, as compared with calcium channel blockers (with or
ithout digoxin) in 72% and digoxin alone in 70%. Similar
ndings were noted with beta-blockers alone (72%) and
alcium channel blockers alone (58%), although digoxin
lone was associated with good rate control with exertion
70%).
nitial overall rate control. The overall goal of rate control
as to achieve a satisfactory HR both during rest and with
able 3. Clinical Characteristics Associated With First Rate-Con
Digoxin Alone
(n  315)
Beta-Blocker*
(n  777)
ge (yrs) 70.1  9.1 69.2  8.7
emales 98 (31.1) 315 (40.5)
on-Caucasian 52 (16.5) 79 (10.2)
AD 112 (35.6) 331 (42.6)
ngina pectoris 74 (23.5) 226 (29.1)
yocardial infarction 48 (15.2) 149 (19.2)
ypass graft surgery 42 (13.3) 105 (13.5)
nterventional procedure 17 (5.4) 91 (11.7)
ypertension 196 (62.2) 564 (72.6)
ardiomyopathy 46 (14.6) 60 (7.7)
ulmonary disease 51 (16.2) 62 (8.0)
revious drug use
Digoxin 239 (75.9) 350 (45.1)
Calcium channel blocker 50 (15.9) 133 (17.1)
Beta-blocker 32 (10.2) 565 (72.7)
aseline heart rate (beats/min) 94.9  29.1 98.1  28.3
inus rhythm at randomization 149 (47.3) 427 (55.0)
A size normal† 88 (33.7) 194 (31.4)
VEF normal‡ 159 (60.9) 432 (69.9)
With or without digoxin. †N  1,509; normal 4.0 cm. ‡By echocardiography; N
atients.
Abbreviations as in Table 2.
Table 4. Cumulative Achievement of Adequat
Initial Drug Therapy
Ov
(n 
BB alone 51/
CCB alone 20/
Digoxin 33/
BB plus digoxin 41/
CCB plus digoxin 31/
BB plus CCB 10/
BB plus CCB plus digoxin 13/
None of the above* 10/
BB with/without digoxin 99/1
CCB with/without digoxin 63/1
BB plus CCB with/without digoxin 23/
*This group consists mostly of patients for whom drug use a
recorded on initial versions of the data form). Also included
as initial therapy, despite being randomized to the rate-contro
patient was counted as having unsuccessful rate control in b
number of patients with atrial fibrillation with successful
Numbers represent the last rate evaluation before any drug cBB  beta-blocker; CCB  calcium channel blocker.xertion. This goal was reached in 70% of patients treated
ith a beta-blocker (with or without digoxin), as compared
ith 54% treated with a calcium channel blocker (with or
ithout digoxin) and 58% with digoxin alone. The use of a
eta-blocker alone showed overall rate control similar to
hat of digoxin alone (59% vs. 58%), with only 38%
dequately controlled with a calcium channel blocker alone.
ate control over time. Adequate overall rate control was
chieved in 58% of patients with the first drug or combi-
ation (Table 4). A total of 635 patients (37%) required a
hange in or the addition of another drug over the course of
ve years. Changes in rate-controlling drug therapy in the
rst year were common: 23% of patients switched from
alcium channel blockers to beta-blockers, 19% switched
Drug Used
Calcium Channel
Blocker* (n  631)
Beta-Blocker and Calcium
Channel Blocker Combined*
(n  138) p Value
70.1  9.2 69.3  9.1 0.2452
278 (44.1) 77 (55.8) 0.0001
74 (11.7) 16 (11.6) 0.0343
208 (33.0) 47 (34.1) 0.0015
142 (22.5) 40 (29.0) 0.0229
87 (13.8) 15 (10.9) 0.0121
51 (8.1) 19 (13.8) 0.0078
44 (7.0) 9 (6.5) 0.0009
449 (71.2) 114 (82.6) 0.0001
45 (7.1) 6 (4.4) 0.0001
133 (21.1) 17 (12.3) 0.0001
344 (54.5) 65 (47.1) 0.0001
469 (74.3) 114 (82.6) 0.0001
96 (15.2) 108 (78.3) 0.0001
104.3  28.7 103.1  29.9 0.0001
361 (57.2) 59 (42.8) 0.0015
189 (36.6) 30 (26.6) 0.8665
369 (71.4) 86 (76.1) 0.0001
09; normal 0.50. Data are presented as the mean value  SD or number (%) of
tricular Rate Control
)
Resting
(n  740)
Exercise
(n  361)
9) 108/159 (68) 62/86 (72)
8) 58/96 (60) 30/52 (58)
8) 92/135 (68) 40/57 (70)
8) 100/133 (75) 52/61 (85)
0) 78/119 (66) 41/52 (79)
9) 22/33 (67) 12/17 (71)
6) 20/27 (74) 15/17 (88)
3) 29/38 (76) 12/19 (63)
0) 245/327 (75) 121/142 (85)
4) 166/252 (66) 84/116 (72)
2) 44/67 (66) 29/37 (78)
tion of therapy was not recorded (this information was not
s group are several patients who took no rate-control drugs
If a patient did not achieve the target resting heart rate, the
e exercise and overall categories. Data are presented as the
l/number of patients with atrial fibrillation evaluated (%).
or addition.trol
 1,5e Ven
erall
361
86 (5
52 (3
57 (5
60 (6
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April 7, 2004:1201–8 Rate Control in AFFIRMrom beta-blockers to calcium channel blockers, and 34%
egan taking either beta-blockers or calcium channel block-
rs after having taken only digoxin. Over time, more
atients taking digoxin or a calcium channel blocker were
hanged to another drug, as compared with patients taking
eta-blockers (p  0.0001) (Fig. 1). Overall rate control,
ate control at rest, and rate control with exertion improved
ver time (Fig. 2).
ate control by HF status. Among patients without HF
ymptoms and with a left ventricular ejection fraction
igure 1. Time to discontinuation of rate-control therapy. Patients are c
igoxin), calcium channel blocker (with or without digoxin), or digoxin al
igure 2. Rate control throughout the AFFIRM study. Time zero is the
ay of randomization. Rate control improved throughout the study.0.40, adequate rate control at rest and exertion, as defined
reviously, was 55% with a beta-blocker (with or without
igoxin), 51% with a calcium channel blocker (with or
ithout digoxin), and 71% with digoxin alone. For patients
ith a history of HF symptoms or a left ventricular ejection
raction 0.40, successful rate control was observed with a
eta-blocker (with or without digoxin) in 81%, with a
alcium channel blocker (with or without digoxin) in 59%,
nd with digoxin alone in 54% at one year.
dverse drug effects. All drug classes used for rate control
ere tolerated reasonably well (Table 5). Serious adverse
ffects were uncommon.
umber of patients in SR. There were 1,055 of 2,027
ate-controlled patients in SR at the time of randomization.
ed by whether they started therapy on a beta-blocker (with or without
Time zero is the day of randomization into the main AFFIRM study.
able 5. Reasons for Discontinuation of Rate-Controlling
rugs
Reason for
Discontinuation
Beta-Blockers
(n)
Calcium Channel
Blockers (n)
Digoxin
(n)
ymptomatic bradycardia 21 16 26
roarrhythmia 0 1 0
ongestive heart failure 14 22 1
yncope 1 2 1
ulmonary 16 0 0
astrointestinal 1 18 7
enito-urinary 3 0 1
entral nervous system 8 10 0
ndocrine 3 1 2
nefficacy 38 63 25
No longer needed” 21 43 51
ther reasons 54 57 21lassifi
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Rate Control in AFFIRM April 7, 2004:1201–8mong these 1,055 patients, 427 (40%) were initially
reated with a beta-blocker (with or without digoxin), 361
34%) were initially treated with a calcium channel blocker
with or without digoxin), and 149 (14%) were initially
reated with digoxin alone. On follow-up, 2,162 (58%),
,349 (56%), and 244 (49%) were in SR at one, three, and
ve years, respectively.
onpharmacologic therapy. A total of 108 patients un-
erwent ablation of the AV junction and insertion of a
ermanent pacemaker to control the ventricular rate during
F. Before ablation, these patients received a mean of 2.4
.7 drug classes for rate control. Combination drug therapy
as not individually reported. Furthermore, a patient might
ave received many different drugs and doses in a class
efore ablation, but would only have been reported as
aving received that drug class. For example, if a patient
eceived propranolol, metoprolol, and atenolol during the
ourse of the study before AV junctional ablation, he or she
ould only have been reported as receiving beta-blocker
herapy. The reasons for undertaking nonpharmacologic
herapy were individual but generally related to failure of
harmacologic therapy.
An additional 147 patients had a pacemaker implanted
or symptomatic bradycardia.
ISCUSSION
entricular rate control is an important aspect of the
anagement of AF. It can improve symptoms, exercise
apacity, and cardiac function (36–40). Although it was not
esigned to assess these rate-control issues specifically in a
andomized method, the AFFIRM study offered the op-
ortunity to evaluate how physicians use rate-controlling
rugs.
Rate control can be difficult, and drugs had to be changed
n approximately one-third of patients. Drug therapy was
ltimately successful by the AFFIRM definitions in two-
hirds of the patients, and rate control improved over time.
ore patients were switched to beta-blockers than to other
rug classes. Often, combination therapy was needed. Few
atients underwent AV junctional ablation.
efinition of adequate rate control. The best criteria for
ate control in AF are not well defined. Effectiveness criteria
sed in the AFFIRM study are based on a consensus of
hat was considered to be reasonable. The criteria may have
een either too lenient or too strict, or the criteria may be
ddressing the wrong issue (ventricular rate, instead of
ymptoms). In many practice settings, the effectiveness of
ate control may not be tested at rest and with frequent
-min walk tests or Holter monitoring. It is not known
hether rate control based on the AFFIRM study guide-
ines has any impact on symptoms or survival.
dequate rate control at rest and with exertion. Rate
ontrol at rest does not ensure rate control with exertion, but
he AFFIRM study showed that use of a functional test was
easible. It is uncertain what rate control criteria provide the iest compromise between hemodynamic and symptomatic
enefit and drug-induced adverse effects. No drug class was
niformly effective. Differences in patients’ clinical charac-
eristics led to a selection bias of one therapy over another.
owever, patients often required multiple drug iterations to
chieve adequate rate control, so initial drug selections based
n disease type and illness severity are unlikely to be
niformly successful.
igoxin. In the AFFIRM study, digoxin was used often as
single drug. Rate control with digoxin during exercise was
imilar to that with beta-blocker use. This finding is
erplexing, but it is possible that digoxin alone was given
rimarily to patients who were chronotropically incompe-
ent, as evidenced by a slower initial ventricular response
ate to AF. Another possibility is that this group was
reselected. Patients whose rate was controlled with digoxin
ad often been started on this drug before enrollment in
FFIRM. It is possible that these results do not portray a
air representation of the effects of digoxin in an unselected
opulation. On the other hand, these data do indicate that
igoxin can be associated with adequate rate control when
he drug is used clinically and selected by clinical criteria. It
as not possible to know the relationship between these
ssues and apparent rate control with digoxin.
Similarly, it appeared that combinations of digoxin with
ther drug classes were associated with improved rate
ontrol. Such results may not be achievable in an unselected
opulation, but as prescribed clinically, rate control can be
chieved with these drug combinations without undue risk.
Drug titration occurred in some patients before enroll-
ent in AFFIRM. The success of initial drug therapy was
hus partly the result of drug exposure before randomiza-
ion. Because no placebo control was used in this trial, it is
ossible that no medication would have worked as well as
igoxin did to control the rate.
alcium channel blockers. Verapamil, alone or in combi-
ation with digoxin, can be superior to digoxin alone in
ecreasing the resting and exercise rate (17). In two studies
6,41), verapamil combined with digoxin improved exercise
apacity. Diltiazem, alone or combined with digoxin, was
imilar to digoxin for control of the resting HR (18), but
igh-dose diltiazem can have frequent adverse effects (19).
erapamil and diltiazem, when combined with digoxin,
ay have similar effects in patients with chronic AF (9).
heir use may be problematic after MI and with HF. In the
FFIRM study, calcium channel blockers were less effective
han beta-blockers at rest and with exertion. More patients
n AFFIRM were switched from calcium channel blockers
o beta-blockers than vice versa.
eta-adrenergic blockers. By using nadolol plus digoxin,
ean and exercise HRs can be reduced, as compared with
igoxin, and the exercise time can be reduced too (23). The
eta1-selective drug, celiprolol, can improve HR control to
xercise at the expense of decreased exercise capacity and
xygen consumption (24). Excessive dosing may result in an
mpaired exercise HR response (25).
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April 7, 2004:1201–8 Rate Control in AFFIRMIn the AFFIRM study, a beta-blocker, used alone or in
ombination with digoxin, or a calcium channel blocker was
ffective, and their use increased with time. Beta-blockers
ay help to maintain SR better than other rate-control
ptions, but it was not possible to evaluate this hypothesis in
he AFFIRM study.
rug changes. In the AFFIRM study, changing from one
ate-controlling drug class to another was common. More
atients were switched to beta-blockers than to other drug
lasses. Drug combinations were associated with improved
ate control. Allowing changes in rate-controlling drugs and
ombination therapy may explain the improved rate control
een in the AFFIRM study over time. The success of
chieving rate control in the AFFIRM study may hinge on
he flexibility of the investigators to use more than one drug
lass for rate control. It is possible that any drug class was
ot fully tested and any drug titration was not complete.
elationship among patient characteristics, initial drug
osing, and rate control. The results from this substudy
o not allow conclusions to be drawn regarding the success
r failure of any specific rate-controlling drug class based on
atient- or disease-specific characteristics. Initial drug se-
ection was partly based on drug use before enrollment in
FFIRM and on the patient’s clinical characteristics. These
election biases could not be controlled in our analysis.
Rate control was possible for the majority of patients, and
t improved over time. Initial rate control may have been
nfluenced by previous drug testing, but long-term rate
ontrol was achievable in this elderly population with AF.
ther methods of rate control. Radiofrequency ablation
f the AV junction (with implantation of a pacemaker) can
e used for rate control in AF. This approach could be
eserved for patients in whom the rate cannot otherwise be
ontrolled. In the AFFIRM study, this method was used
nfrequently.
tudy limitations. The treating physician was free to
hoose the first drug administered. Drug use was partly
ependent on historical and clinical variables. Drugs used
efore randomization in the AFFIRM study influenced first
rug use after randomization. Neither the patient nor
nvestigator was blinded to the study drugs. Patients in SR
t any time point were not included in the percent success of
ate control at that time point. Rate control was analyzed by
rug class, not by individual drug, and doses and start/stop
ates were not reported. It is important to emphasize that
here was no placebo group in this study, and there was no
andatory baseline period during which drug therapy was
rohibited. Drug selection, dose selection and titration, and
rug changes were discretionary. We could not exclude the
ontribution of natural changes in AV nodal conduction
ith time. Without a placebo control group or washout
eriod, it was not possible to assess the mechanism of
mproved rate control over time.
onclusions. Based on rate-control criteria developed for
he AFFIRM study, most patients have an adequate re-
ponse to the available drug classes, although frequentedication changes may be necessary and combinations
ay be needed. Based on the results of this study, beta-
lockers tend to be used more commonly over time, and
ewer patients abandoned this drug class.
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